Identification of the IGF-1 processing product human Ec/rodent Eb peptide in various tissues: Evidence for its differential regulation after exercise-induced muscle damage in humans.
Insulin-like growth factor-1 (IGF-1) is a pleiotropic factor expressed in various tissues and plays a critical role in skeletal muscle physiology. Alternative splicing of the IGF-1 gene gives rise to different precursor polypeptides (isoforms) which could undergo post-translational cleavage, generating the common mature IGF-1 peptide and different carboxyl terminal extension (E-) peptides, with the fate of the latter being, so far, unknown. The objective if this study was to identify the IGF-1Ec forms or processing product(s), other than mature IGF-1, generated in different human and rodent tissues and particularly in human skeletal muscle after exercise-induced damage.



Protein lysates from a wide range of human and rodent tissues were immunoblotted with a rabbit anti-human Ec polyclonal antibody raised against the last 24 amino acids of the C-terminal of the Ec peptide. This antibody can recognize the Ec peptide, both as part of IGF-1Ec and alone, and also the corresponding rodent forms, due to the high homology that the human Ec shares with the rodent Eb.



We were able to confirm, for the first time, that the human Ec peptide and its rodent homologous Eb peptide are produced simultaneously with their precursor protein (pro-IGF-1Ec/Eb) in vivo, in a wide range of tissues (e.g. muscle, liver, heart). Proprotein convertase furin digestion of human muscle and liver protein lysates confirmed that the higher molecular form, pro-IGF-1Ec, can be cleaved to produce the free Ec peptide. Furthermore, initial evidence is provided that Ec peptide is differentially regulated during the process of muscle regeneration after exercise-induced damage in humans.



The findings of this study possibly imply that the post-translational modification of the IGF-1Ec pro-peptide may regulate the bioavailability and activity of the processing product(s).
Department of Experimental Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
George
G
Vassilakos
Department of Experimental Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Anastassios
A
Philippou
Department of Experimental Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: mkoutsil@med.uoa.gr.
Michael
M
Koutsilieris
D017398:Alternative Splicing; D000818:Animals; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000235:genetics / Q000378:metabolism*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018482:Muscle, Skeletal / Q000293:injuries / Q000503:physiopathology*; D010446:Peptide Fragments / Q000378:metabolism*; D020033:Protein Isoforms; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution
C583557:IGF1 protein, human; D010446:Peptide Fragments; D020033:Protein Isoforms; D007334:Insulin-Like Growth Factor I
Ec/Eb peptide; IGF-1Ec forms; Muscle damage; Post-translational processing; Pro-protein cleavage